# A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

> **NCT00635817** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 84 (actual)

## Conditions studied

- Puberty, Precocious

## Interventions

- **DRUG:** Leuprolide acetate 11.25 mg
- **DRUG:** Leuprolide acetate 30 mg

## Key facts

- **NCT ID:** NCT00635817
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-06
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635817, "A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00635817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*